Elon Musk intends to employ the Neuralink brain device to reduce fat which can open gates to future
In the past, Musk proposed that severe depression, morbid obesity, and sleep problems may be treated with BCIs.
Renowned entrepreneur Elon Musk's proposal to utilize Neuralink, his brain-computer interface (BCI) venture, for weight loss has sparked safety concerns among experts.
While Musk had previously suggested that BCIs could address severe depression, morbid obesity, and sleep disorders, critics are wary of the invasive nature of BCI procedures, involving brain surgery and potential risks, making them less preferable compared to alternative weight-loss interventions.
Although BCIs like Neuralink have proven successful in aiding individuals with paralysis, the idea of using them for weight control raises ethical and safety considerations. The US Government Accountability Office has highlighted surgical risks such as infection and rejection associated with implanted BCIs.
In contrast, a new class of drugs known as "glucagon-like peptide 1 agonists" (GLP-1s) is emerging as a safer and more effective option for weight loss. Initially designed for diabetes treatment, GLP-1s have demonstrated appetite-suppressing effects by slowing the movement of food through the digestive system. Recently, the US Food and Drug Administration approved Eli Lilly's GLP-1 drug, Zepbound, specifically for obesity treatment.
The safety and efficacy of GLP-1 drugs, administered through injections, have been affirmed through large-scale trials. Importantly, these drugs are recommended in conjunction with a reduced-calorie diet and increased physical activity.
Experts emphasize that GLP-1 drugs offer a molecular approach to hunger control with fewer risks compared to invasive BCI procedures. While critics highlight the potential for abuse and adverse effects associated with hunger-controlling interventions, whether through implants or drugs, medical professionals argue that proper screening can identify individuals at risk of eating disorders, minimizing potential harm.
The historical precedent of the Minnesota Starvation Experiment underscores the complex relationship between food restriction and psychological effects, emphasizing the importance of cautious approaches to weight-loss interventions.
In conclusion, the availability of safe and effective GLP-1 drugs suggests a more viable path for weight-loss interventions than invasive BCIs. Experts urge thorough exploration of alternative options, including lifestyle changes and pharmaceutical interventions, before considering experimental brain-chip procedures for conditions with established, safer alternatives.
